Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-292 in RET Fusion-Positive Stage IV or Recurrent NSCLC (LUNG-MAP Sub-Study)
NCT04268550Phase 2Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2020
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started Apr 2020; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04268550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268550.